Tootsie Roll's Q2 2026 profit slump forces downgrade from Hold to Sell

What happened

Tootsie Roll's fiscal Q2 2026 results showed a revenue dip with domestic sales down 2.5%, while a 25.1% surge in foreign sales failed to offset the decline. Net income fell sharply to $13.3 million as higher cocoa costs pushed up COGS and compressed margins, confirming that extended chocolate supply contracts continue to lock in elevated input prices into 2026. The company's strong balance sheet—roughly $527 million in cash and investments against minimal debt—offers downside protection, but the stock still trades at a premium ~33x trailing earnings, leaving little valuation cushion. The non-chocolate product skew, previously a relative hedge against cocoa volatility, did not prevent meaningful profitability deterioration in the quarter. The latest evidence prompts a downgrade from Hold/Neutral to Sell, as margin recovery now appears further out and the valuation remains rich.

Implication

Investors should note that the combination of a premium valuation and deteriorating fundamentals creates asymmetric downside: Q2 2026 net income of $13.3 million annualizes to roughly $0.19 per share, implying an elevated trailing P/E and weak earnings power. The foreign sales surge (+25.1%) is a positive but too small relative to the domestic decline (-2.5%) and likely reflects low-margin export or timing shifts rather than a durable mix improvement. Cocoa cost contracts signed through 2026 continue to pressure gross margin, and until those contracts roll off at lower spot prices, profitability will remain subdued. The strong net cash position provides downside support, but it won't prevent multiple compression if earnings continue to miss. We would avoid adding exposure; existing holders may use rallies to reduce until there is evidence of gross margin recovery above pre-2024 levels and domestic sell-through improvement.

Thesis delta

Prior HOLD/NEUTRAL was predicated on durable brands, non-chocolate skew, and balance-sheet support, with margin recovery expected as cocoa eased. Q2 2026 results refute that timeline: domestic revenue decline and net income collapsing to $13.3 million show margin compression is more severe than modeled, while the stock still trades at a premium. We shift to SELL/UNDERWEIGHT; the thesis shift is triggered by actual deterioration rather than mere risk flag.